|
See related Exjade dispersible tab information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Hong Kong: Zuellig/Macau: Four Star |
|
Contents |
Deferasirox |
|
Indications |
Treatment of transfusion-induced haemosiderosis.
Click to view Exjade detailed prescribing infomation |
|
Dosage |
Initially 20 mg/kg once daily.
Click to view Exjade detailed prescribing infomation |
|
Overdosage |
View Exjade overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken on an empty stomach (Take on an empty stomach at least 30 min before meals, preferably at the same time daily. Disperse the tab by stirring in 100-200 mL of water or orange juice until a fine susp is obtained. After the susp has been drunk, any residue must be resuspended in a small vol of water or orange juice & drunk. Do not chew/swallow the tab.). |
|
Contraindications |
CrCl <40-60 mL/min or serum creatinine >2 times the age-appropriate upper limit of normal. Patients w/ high risk myelodysplastic syndrome, & other hematological & non-hematological malignancies.
Click to view Exjade detailed prescribing infomation |
|
Special Precautions |
Renal & hepatic impairment. Assess serum creatinine prior to therapy & mthly thereafter. Monitor liver function mthly. Skin rash. Perform auditory & ophth testing before treatment & at regular intervals. Monitor body wt & longitudinal growth at regular intervals in childn. Pregnancy & lactation.
Click to view Exjade detailed prescribing infomation |
|
Adverse Drug Reactions |
Headache, diarrhoea, constipation, vomiting, nausea, abdominal pain, abdominal distension, dyspepsia, elevated transaminases, rash, pruritus, proteinuria, increased serum creatinine.
View ADR Monitoring Form |
|
Drug Interactions |
Al-containing antacids, apple juice.
View more drug interactions with Exjade |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Exjade storage conditions for details to ensure optimal shelf-life. |
|
Mechanism of Action |
View Exjade mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
